SCHEMBL1948726

SCHEMBL1948726

Clc1ccc(COc2ccc(OCc3ccc(Cl)cc3)c(-c3c[nH]cn3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MAOB P27338 15/20 0.43
MAOA P21397 9/20 0.43
APP P05067 1/20 0.42
MPO P05164 1/20 0.40
ACHE P22303 1/20 0.40
SLC6A4 P31645 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13673987 0.87 MAOB (0.40) MAOBMAOAAPPMPOACHE
SCHEMBL1950888 0.86 CCR5 (0.52) SLC6A4
SCHEMBL1948653 0.83 SMN1; SMN2 (0.47)
SCHEMBL1951907 0.83 SLC6A4 (0.45) MPOSLC6A4
SCHEMBL13516738 0.72 NPC1 (0.50) SLC6A4
SCHEMBL1951712 0.72 SGMS2 (0.50) MPOSLC6A4
SCHEMBL1906514 0.71 KMT2A (0.37) MAOBAPP
SCHEMBL1948178 0.71 BRD4 (0.56)
SCHEMBL12676451 0.70 KMT2A (0.55) SLC6A4
SCHEMBL12676654 0.70 CNR1 (0.43) MAOBMAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110136796-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-06-09 US claimed
US-9174942-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2015-11-03 US disclosed
US-9174942-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2015-11-03 US disclosed
US-9174942-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2015-11-03 US disclosed
US-20140323740-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION (US) 2014-10-30 US disclosed
US-20140323740-A1 IDO Inhibitors NEWLINK GENETICS CORPORATION (US) 2014-10-30 US disclosed
US-8748469-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2014-06-10 US disclosed
US-8748469-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2014-06-10 US disclosed
US-8748469-B2 IDO inhibitors NEWLINK GENETICS CORPORATION (US) 2014-06-10 US disclosed
US-20110136796-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-06-09 US disclosed
US-20110136796-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-06-09 US disclosed
US-20110136796-A1 IDO Inhibitors NEWLINK GENETICS (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323740-A1 IDO Inhibitors IDO1, IDO2, INMT MAOB 28/4885MAOA 20/4885APP 4577/4885
US-20110136796-A1 IDO Inhibitors IDO1, IDO2, INMT MAOB 28/4885MAOA 20/4885APP 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.